Evidence & References GLP-1 receptor agonists may reduce metastatic progression of certain obesity-related cancers
They cannot by themselves establish: A safe human amount A safe route of administration Long-term human safety Interaction risks Reproductive or developmental safety Clinical effectiveness Which individuals, if any, might be suitable for an authorised use The number of animal papers should not be presented as equivalent to a programme of large, well-controlled human clinical trials
Semaglutide, liraglutide, and dulaglutide have all shown to reduce the occurrence of major cardiovascular events like heart attack, stroke, and death in patients with diabetes, while tirzepatide is currently being studied for the same
Reducing hunger and appetite
What Makes one LifeWave Patch Different than Another
rda Abdrabou Abouelmagd i in., (2025)